Scientists have long known that the loss of olfactory capacity, or ability to smell, can predict development of nearly 70 neurological and psychiatric diseases. These include Alzheimer's and other dementias, Parkinson's, schizophrenia and alcoholism. Evidence is emerging about a link between smell loss due to COVID and ensuing cognitive decrease....
Phyllodulcin, a natural sweetener found in Hydrangea macrophylla var. thunbergii, shows potential for treating Alzheimer's disease (AD).
An article published in the journal Lancet Neurology evaluates the risk of recurrence of active disease in older patients with multiple sclerosis after discontinuing disease-modifying therapies.
Seniors who took low-dose aspirin daily for primary prevention had no reduction in the risk for first strokes in a large randomized trial that followed them for about 5 years (Daily Aspirin Challenged in Primary Stroke Prevention: ASPREE).
Is myocardial infarction (MI) associated with cognition acutely after MI or in the years following MI?
Solanezumab, a monoclonal antibody that binds to the monomeric or soluble form of amyloid-beta, is no better than placebo in slowing the progression of preclinical Alzheimer's disease (AD), results of a phase 3 trial show.
Initiating treatment for multiple sclerosis (MS) within 6 months of the first symptoms is associated with a significantly lower risk for severe disability one decade later, a new study suggests (Neurology. Published online July 19, 2023).
In a new study the authors examined whether cerebrospinal fluid (CSF) baseline levels of the synaptic protein NPTX2 predict time to onset of symptoms of Mild Cognitive Impairment (MCI), both alone and when accounting for traditional CSF Alzheimer's disease (AD) biomarker levels.
A new study demonstrates intensive exercise could decelerate the progression of Parkinson's disease by influencing brain plasticity. The research uncovers a novel mechanism underlying the positive effects of exercise, pinpointing its connection to motor control improvements.
A new study published in PLOS ONE sheds light on how certain anti-inflammatory drugs may prove to be effective treatments for Alzheimer's disease (AD).
